Objective:

To investigate whether Scrambler therapy with duloxetine is superior to duloxetine-based usual care in achieving at least a 50% reduction in pain scores for patients with chemotherapy-induced peripheral neuropathy (CIPN), with a primary endpoint of pain score comparison at day 35.

Key Findings:

• Primary outcome is a 50% reduction in pain scores at day 35 compared to baseline, indicating significant clinical improvement.
• Inclusion criteria include adults with cancer and a minimum average pain score of 4/10, ensuring a relevant patient population.

Interpretation:

The study aims to determine the efficacy of Scrambler therapy in reducing CIPN-related pain compared to standard duloxetine treatment.

Limitations:

• Exclusion of children, pregnant or nursing patients, and those with certain medical conditions may limit generalizability.
• Patients currently on gabapentin must be able to wean off for treatment eligibility, which may affect recruitment.

Conclusion:

The trial seeks to provide insights into the effectiveness of Scrambler therapy for managing CIPN pain, potentially influencing future treatment protocols.